Amyloidosis is a term referring to a group of complex diseases that are caused by protein misfolding and aggregation into highly ordered amyloid fibrils that deposit in tissues, resulting in progressive organ damage. These amyloid fibrils are characterized by a cross-β-sheet quaternary structure 1 . Over time, protein misfolding and amyloid accumulation can result in severe organ dysfunction. Protein aggregates, or preceding intermediaries, may induce cell dysfunction and death, a process termed proteotoxicity. In addition, the distortion of tissue architecture caused by amyloid deposits contributes to organ dysfunction 2 ; however, these disease mechanisms are poorly characterized.
To date, 36 proteins that can form extracellular amyloid fibrils in humans have been identified: some form localized deposits, such as β-amyloid in Alzheimer disease, leading to localized amyloidosis, and others accumulate throughout the tissues of the body (known as systemic amyloidosis) 3 . At least 17 proteins can cause systemic amyloidosis; immunoglobulin heavy or light chains are notable in being able to form both systemic amyloid deposits and localized amyloid deposits, for example, those restricted particularly to urothelial tissue and the larynx 4 . Systemic amyloidosis can be hereditary or acquired; the two most common forms of systemic amyloidosis -monoclonal immunoglobulin light chain amyloidosis (known as AL amyloidosis) and wild-type transthyretin amyloidosis (known as ATTR amyloidosis) -are acquired. AL amyloidosis is typically found in individuals with monoclonal gammo pathy, a disorder that is characterized by the proliferation of clonal plasma cells, and is caused by the increased production of immunoglobulin light chains; these light chains aggregate into amyloid fibrils, leading to organ damage. Wildtype ATTR amyloidosis is caused by the aggregation of transthyretin, is age related and predominantly affects men >70 years of age. Another form of non-hereditary systemic amyloidosis is caused by persistently high concentrations of serum amyloid A protein (an acute phase reactant), which is associated with chronic inflammation caused by chronic inflammatory disorders such as rheumatoid arthritis, persistent infections or hereditary autoinflammatory diseases (familial Mediterranean fever, cryopyrin-associated periodic syndrome and many others) 5 . Systemic amyloidosis caused by leukocyte chemotactic factor 2 mainly presents with nephropathy and is gaining greater recognition in the United States 6 . Systemic amyloidosis can also be caused by genetic mutations inherited in an autosomal dominant manner. More than 120 point mutations in TTR (encoding 1, 2 , Philip N. Hawkins 6 and Morie A. Gertz 3 Abstract | Systemic immunoglobulin light chain amyloidosis is a protein misfolding disease caused by the conversion of immunoglobulin light chains from their soluble functional states into highly organized amyloid fibrillar aggregates that lead to organ dysfunction. The disease is progressive and, accordingly , early diagnosis is vital to prevent irreversible organ damage, of which cardiac damage and renal damage predominate. The development of novel sensitive biomarkers and imaging technologies for the detection and quantification of organ involvement and damage is facilitating earlier diagnosis and improved evaluation of the efficacy of new and existing therapies. Treatment is guided by risk assessment, which is based on levels of cardiac biomarkers; close monitoring of clonal and organ responses guides duration of therapy and changes in regimen. Several new classes of drugs, such as proteasome inhibitors and immunomodulatory drugs, along with high-dose chemotherapy and autologous haematopoietic stem cell transplantation, have led to rapid and deep suppression of amyloid light chain production in the majority of patients. However, effective therapies for patients with advanced cardiac involvement are an unmet need. Passive immunotherapies targeting clonal plasma cells and directly accelerating removal of amyloid deposits promise to further improve the overall outlook of this increasingly treatable disease.
Systemic immunoglobulin light chain amyloidosis
trans thyretin) can cause systemic amyloidosis that mainly affects the peripheral nervous system and the heart. Genetic variants of APOA1, APOA2, APOC2 and APOC3 (encoding apolipoprotein AI, apolipoprotein AII, apolipoprotein CII and apolipoprotein CIII, respectively), as well as FGA (encoding fibrinogen α chain), GSN (encoding gelsolin), CST3 (encoding cystatin C) and LYZ (encoding lysozyme), can also cause hereditary systemic amyloidosis 3 ( Table 1) .
Despite the biochemical and aetiological heterogeneity of systemic amyloidosis, the clinical manifestations of the different forms largely overlap and essentially depend upon the affected organs. Predominantly affected organs include the kidney and heart, followed by the peripheral nervous system (including the autonomic nervous system), liver, gastrointestinal tract and soft tissues. Cardiac damage is a major determinant of survival, therefore, a major goal of therapy is to improve cardiac function. A rapid and profound decrease of the amyloid precursor protein can reverse organ dysfunction and is the aim of therapy. In AL amyloidosis, therapy is aimed at targeting the B cell clone responsible for producing the aberrant clonal immunoglobulin protein.
The type and intensity of treatment targeting the B cell disease are based on risk assessment, which is based on the characteristics of the patient and the biology of the clone. Immunotherapies targeting the amyloid clone or the amyloid deposits are now in development; hopefully, these new agents will enter clinical practice and will be combined with therapies to suppress the amyloid protein, which might improve quality of life (QOL) and survival.
This Primer focuses on systemic AL amyloidosis, highlighting the disease mechanisms and basis for effective treatment, owing to advances in deciphering the molecular mechanisms of this form of amyloidosis and in developing novel, effective therapies that have improved QOL and survival 7, 8 .
Epidemiology
Limited data on the epidemiology of AL amyloidosis are available owing to the lack of large population databases to assess incidence. The prevalence of the disease rises with increasing age; prevalence doubles in individuals aged >65 years compared with those aged 35-54 years, with a reported mean age at diagnosis of 63 years, and 55% of patients are men 9 . There are two known risk factors for AL amyloidosis. The first is a preexisting monoclonal gammopathy. Among patients with monoclonal gammopathy of undetermined significance (MGUS), the relative risk of developing AL amyloidosis is 8.8 (ref.
10
) compared with individuals without MGUS. In one series of 1,384 patients with MGUS followed up for up to 50 years, 14 developed AL amyloidosis (1%). As many as 10-15% of patients with myeloma have overt, coexisting AL amyloidosis, and in another series, as many as 38% of patients with myeloma were found to have covert coexisting AL amyloid osis 11 . Approximately 1% of patients with pre-existing myeloma, who are not simultaneously diagnosed with AL amyloidosis, will go on to develop AL amyloidosis 12 . Antecedent viral infection does not seem to be a predisposing factor.
The other identified risk factor for AL amyloidosis is the existence of particular single nucleotide poly morphisms (SNPs). Associations were found in a genome-wide association study on a cohort of 1,229 patients with AL amyloidosis. SNPs at ten loci showed evidence of an association (P < 10 −5 ). Within the splice site of CCND1 (encoding cyclin D1), the variant rs9344, which promotes a translocation between chromosomes 11 and 14 (t (11;14) ), reached the highest significance (P = 7.80 × 10 −11 ). The SNP rs79419269, which is close to the gene SMARCD3 that encodes a protein involved in chromatin remodelling, was also significant (P = 5.2 × 10 −8 ). These data provide evidence for common genetic susceptibility to AL amyloidosis 13 .
Incidence of AL amyloidosis
Six studies have evaluated the incidence of systemic AL amyloidosis, all of which were carried out in the Americas and Europe [14] [15] [16] [17] [18] [19] (Table 2 ). The first study was carried out using the Olmsted County Project in Minnesota, USA, and reported an overall sex-adjusted and age-adjusted rate of 8. A forthcoming update to this study that included patients from the same region between 1990 and 2015 demonstrated an incidence of 12 affected individuals per million per year, which did not significantly differ from that reported in the earlier study. The only other true population-based study of the incidence of systemic AL amyloidosis was carried out in the Limousin region of France from 2012 to 2016 (ref. 18 ). This study demonstrated a crude yearly incidence of 12.5 affected individuals per million inhabitants over the 5-year period studied. The four other studies were not true population-based studies and ascertained the incidence on the basis of death certificate reports and hospital discharges, among other methods [15] [16] [17] 19 . One study extrapolated the incidence from referral rates to the UK National Amyloidosis Centre, death certificates and the distribution of types of systemic amyloidosis cases seen at the centre 15 and estimated an incidence of at least three affected individuals per million person-years in England in 2008. A study in Sweden used myeloma statistics and amyloid hospital discharge diagnoses to derive an annual incidence of three affected individuals per million person-years between 2001 and 2018 (ref.
16
).
An incidence of 6.1 per million person-years adjusted for the population of Buenos Aires, Argentina, (2010 census) was based on 12 persons with AL amyloidosis 19 . These investigators designed a prospective cohort of all members of a prepaid health maintenance organization in Buenos Aires between 2006 and 2015. They calculated the number of incident cases of amyloidosis per one million person-years and adjusted it using the Buenos Aires Census of 2010. Lastly, another study estimated the incidence of AL amyloidosis using US claims data between 2007 and 2015 (ref. 17 ) and reported an age-adjusted and sex-adjusted incidence of 10.8-15.2 affected individuals per million person-years. However, this estimate might be high, as this study differentiated patients with AL amyloidosis from other forms of amyloidosis on the basis of the receipt of ' AL amyloidosis defining therapies' , which included therapies that are not specific for AL amyloidosis. For example, doxycycline was included in this category despite the fact that its use is by no means specific for AL amyloidosis. The differences between studies most likely relate to methodology and the somewhat small numbers of events. The studies with the most epidemiologically sound designs yielded very similar results 14, 18, 19 .
Prevalence
The prevalence of systemic AL amyloidosis has increased owing to improved therapies and improved overall survival of patients. Indeed, prevalence estimates were between 8.8 and 15.5 affected individuals per million 3 Nature reviews | Disease Primers | article citation iD:
(2018) 4:38 3 P r i m e r 0123456789(); . This annual percentage change existed for both males (11.5%) and females (12.3%) 17 .
Mechanisms/pathophysiology Amyloid fibril formation As previously mentioned, the process underlying amyloidosis is the conversion of globular, soluble proteins into insoluble amyloid fibrils that deposit in vital organs and damage their functions 1 . This complex process can be favoured by several factors, such as mutations that destabilize the native protein structure and expose hydrophobic and protease-sensitive regions, increased protein concentrations, owing to either greater protein synthesis or reduced clearance, or the intrinsic propensity of certain proteins to form amyloid fibrils that becomes apparent with ageing. Typically, protein aggregation is countered by protein homeostasis (proteostasis) that functions to maintain the proteome, both intracellularly and extracellularly, in a native conformation, in the correct location and at the right concentration 20, 21 . Overall, ~1,600 molecules have a role in proteostasis, the efficiency of which declines with age 22 . When intracellular proteostasis and/or extracellular proteostasis fail, protein aggregation might occur. Proteins with diverse structures and functions can aggregate to form amyloid fibrils, which have highly ordered cross-β-fibre structures and are characterized by antiparallel β-strands that are arranged perpendicular to the fibre, as demonstrated by X-ray diffraction 23 . Amyloid fibrils have a distinct diameter of 7.5-10.0 nm as determined using electron microscopy 24 .
AL amyloidosis fibril formation. AL amyloidosis is usually caused by the low-level expansion of an indolent B cell clone 25 that produces an immunoglobulin light chain λ (referred to as light chain in this Primer) in 75-80% of cases and κ light chains in the remaining cases ( fig. 1) . A high frequency (~40-60%) of chromosomal t (11;14) , which juxtaposes the immunoglobulin heavy chain (IGH) locus to the oncogene CCND1, characterizes this amyloid B cell clone 26 . Somatic mutations in IGLV (encoding the light chain variable region) reduce the fold stability of the native protein and increase protein dynamics, which favours endoproteolysis and the prod uction of variable light chain domains that can cause amyloidosis 27 . Indeed, amyloidogenic light chains have a low fold stability and high protein dynamics compared with the light chains Somatic mutations in the light chain variable region (IGLV) gene cause low folding stability and increased protein dynamics, which favour protein misfolding and improper aggregation. In addition, interactions between the protein and the tissue micro environment, including extracellular matrix components, shear forces, endoproteases and metals, favour protein aggregation and oligomer formation. Cells may promote the initial nucleation of the deposits through interaction of the amyloid protein with cell membranes. Oligomers, and probably the misfolded protein, exert toxic effects by impairing cell function and reducing cell viability in target organs and can develop into highly organized cross-β-amyloid fibrils. Serum amyloid P component (SAP) protects amyloid fibrils from degradation and is ubiquitously present in amyloid deposits. Glycosaminoglycans serve as scaffolds and facilitate fibril formation. The accumulation of amyloid deposits in parenchymal tissue leads to tissue damage, which causes dysfunction of vital organs; moreover, amyloid fibrils can cause cell damage and catalyse oligomer formation. b | AL amyloid fibrils have a propensity to accumulate in specific organs. In particular, light chains derived from certain genes show a propensity to target specific organs: light chain λ from IGLV1-44 preferentially targets the heart, light chain λ from IGLV6-57 targets the kidney and light chain κ from IGKV1-33 targets the liver. produced in multiple myeloma 28, 29 . In proteostasis, extracellular chaperones favour appropriate light chain folding and inhibit protein aggregation 30 . The aggregation of amyloidogenic light chains can occur owing to disruption to, or overwhelming of, extracellular proteostasis ( fig. 1 ). Other factors can facilitate protein aggregation and oligomer formation, such as the interactions of amyloidogenic light chains with the tissue microenvironment, including with extracellular matrix components (such as glycosaminoglycans, collagen and lipids) 31 , shear forces, proteases and metals (in particular, copper) 32 . In addition, cell membrane surfaces have been hypothesized to facilitate fibril attachment by acting as anchors for a cell-mediated seeding mechanism 33 . Once formed, oligomers of light chains are on the pathway to form highly organized amyloid fibrils. The pentraxin serum amyloid P component (SAP) is a circulating plasma protein that is universally present in amyloid deposits owing to its calcium-dependent binding to amyloid fibrils 34 . SAP has been reported to protect amyloid fibrils from degradation 35 , making this protein an excellent candidate for amyloid scintigraphy and as a target for amyloid-directed immunotherapy. The accumulation of amyloid deposits in parenchymal tissue leads to tissue damage, which causes dysfunction of vital organs 2 . In addition, amyloid fibrils cause cytotoxicity and promote the misfolding of light chains and further oligomer formation 33 . Soluble prefibrillar species, mainly oligomers, also contribute to organ damage through proteotoxicity and increased cellular oxidative stress, resulting in mitochondrial damage and reduced cell viability [36] [37] [38] (fig. 1 ).
The kinetics of fibril formation offer important clues for clinical management ( fig. 2) . The formation of amyloid fibrils begins from a solution of the monomeric native protein, which might misfold and assume an amyloidogenic, partially folded conformation. When the amount of partially folded proteins reaches a specific concentration, a critical fibrillar nucleus forms, which catalyses protein aggregation and fibril development. The critical concentration required for nucleation varies and can be very low for very unstable light chains or high for more stable light chains. Initially, conditions do not favour aggregation, which corresponds to the lag phase that precedes fibril formation. The kinetics of aggregation dramatically change after formation of the fibrillar nuclei owing to their catalytic role. The concentration of partially folded proteins that is necessary to elongate the amyloid fibrils is 10-fold to 20-fold lower than the concentration required for forming the first fibrillar nucleus, depending on the protein species 39 . Thus, early diagnosis of AL amyloidosis and administration of a rapidly acting therapy that produces a swift and deep reduction of the amyloid precursor are critical to halt fibril growth and disease progression. Amyloid deposits are in general persistent and unusually resistant to degradation. However, slow natural clearance of amyloid deposits, by endogenous immunological mechanisms in which macrophages play an important part, does occur 40 . Clearance of amyloid deposits may contribute considerably to recovery of organ function 2 .
Organ involvement
The heart and the kidneys are the two most frequently affected organs in systemic AL amyloidosis, although all organs can be involved, except the brain ( fig. 3 ). The precise molecular mechanisms underlying amyloid organ targeting remain elusive. Several investigators have shown that certain structural features related to the IGLV gene and gene family confer a higher risk of involvement of specific organs, possibly through interactions with resident cells. For example, the germline gene (that is, the unarranged gene inherited through the germ line before modification by rearrangement and somatic hypermutation) IGLV6-57 is more common in patients with AL systemic amyloidosis than in the normal B cell repertoire and is associated with renal involvement 41 . Mesangial cells of the kidney have a propensity to form amyloid fibrils when incubated with light chain derived from IGLV6-57 (ref.
41
). Cardiac tropism has been related to the IGLV1-44 germline gene, which confers a fivefold increase in the chance of dominant heart involvement 42, 43 . Although λ light chains are responsible for most cases of systemic AL amyloidosis, the κ light chain of the IGKV1-33 germline gene preferentially targets the liver 43 . Cardiac involvement is a key determinant of patient survival; thus, several investigators have studied the mechanisms of cardiac damage caused by misfolded light chain [36] [37] [38] . Cardiac dysfunction can result from amyloid deposits that cause widespread disruption of tissue architecture, and from proteotoxicity of the light . Other speculated mechanisms of organ dysfunction include the perturbation of cellular membranes by amyloid fibrils, cell toxicity owing to fibril growth and the formation of soluble light chain oligomers by amyloid fibrils, although these mechanisms require further study. In addition, AL amyloid fibrils are cytotoxic at low concentrations, whereas soluble amyloid light chains induce apoptosis, suggesting that the mechanisms of cytotoxicity differ between soluble protein and amyloid fibrils 33 . Exposing cardiac cells to light chains purified from patients with cardiac AL amyloidosis led to the increased production of reactive oxygen species (ROS) compared with the levels produced from control light chain proteins isolated from patients without cardiac involvement 32, 37 . Amyloidogenic light chains from patients with AL amyloid cardiomyopathy can induce p38 mitogenactivated protein kinase (MAPK) signalling, resulting in increased production of ROS, impaired calcium homeostasis, cell dysfunction and eventually cell death in isolated adult cardiomyocytes 36 . This p38 MAPK pathway also mediates the transcription of type B natriuretic peptide (BNP), a serum biomarker of cardiac stretch and damage 44 , supporting a possible connection between cardiotoxic effects of light chain with induced MAPK signalling and BNP. This pathogenetic link is the basis of the use of the serum biomarker NT-proBNP (the amino-terminal fragment of BNP) in the management of patients with AL, and its use ranges from early detection of cardiac involvement to risk classification and monitoring of cardiac response to therapy 45 . Diagnosis, screening and prevention A diagnosis of amyloidosis should be considered in any patient presenting with heart failure with preserved ejection fraction, nephrotic range proteinuria, a mixed axonal demyelinating peripheral neuropathy with autonomic features or carpal tunnel syndrome, hepatomegaly without imaging abnormalities, or in any patient with a monoclonal gammopathy or atypical multiple myeloma. In addition, taste alterations are a common sign 7, 46 ( fig. 3 ).
In any patient with these clinical signs and symptoms, at a minimum, immunofixation electrophor esis of the serum and urine and an immunoglobulin free light chain assay (which assesses the concentration of κ and λ free light chains and their ratio in the serum) should be carried out to assess for a precursor light chain protein. Where available, imaging with radio-iodinated SAP can identify amyloid deposits in individuals with these syndromes 47 , but this test has limited availability and is restricted to certain specialized amyloidosis treatment centres. Tissue biopsy and histopathological analysis to confirm diagnosis are warranted in patients with an immunoglobulin light chain abnormality (fig. 4) . The ordered ultrastructure of amyloid fibres enables the regular intercalation of Congo red dye, which shows green birefringence under polarized light microscopy; the diagnosis of AL amyloidosis amyloidosis are variable and mimic symptoms observed in common conditions of elderly individuals, such as heart failure (fatigue) and diabetes mellitus (proteinuria and peripheral neuropathy), therefore, contributing to late diagnosis. The presence of heart failure with preserved ejection fraction and thickened ventricular walls with low voltages identified using electrocardiography should raise the suspicion of cardiac amyloidosis. Kidney involvement is characterized by proteinuria and progressive renal failure and manifests as peripheral oedema. The involvement of the gastrointestinal tract results in malabsorption and weight loss that can be prominent in some patients, whereas involvement of the autonomic nervous system can cause invalidating postural hypotension. The presence of prototypic signs such as macroglossia (enlargement of the tongue) and periorbital purpura can immediately lead to the right diagnosis. However, such signs are uncommon and, more importantly , appear late in the course of the disease, frequently appearing when the organ damage caused by amyloid is already irreversible. requires this histologi cal observation ( fig. 5 ). Although the direct biopsy of an affected organ will yield the diagnosis, it is generally not necessary, as less invasive investigations such as the aspiration of subcutaneous fat, a bone marrow biopsy or a lip biopsy can lead to diagnosis in 50-85% of patients 48, 49 . When amyloid deposits are detected in biopsy samples, accurate identification of the precursor protein is crucial to guide treatment. This is feasible using immunohistochemistry, in highly specialized laboratories 50, 51 , and using immune-electronmicroscopy 52 . However, a mass spectrometry-based analysis of the amyloid-containing tissues is now considered the best approach, with a reported sensitivity of 88% and specificity of 96% higher than immunochemical techniques. Furthermore, mass-spectrometry-based analysis does not require a large panel of antisera to identify non-AL amyloidosis 53 . Although not widely available, reference laboratories exist that will unequivocally confirm the protein subunit composing the amyloid fibril. This is particularly important in individuals of black ethnicity, given that the prevalence of V122I-mutant ATTR is high in this population, and ATTR-V122I amyloidosis can clinically resemble AL amyloidosis 54 .
Differential diagnosis
Diagnosing AL amyloidosis on the basis of the presence of a serum and/or urine light chain abnormality and a Congo red-positive tissue biopsy is insufficient. As many as 23% of patients with wild-type ATTR cardiac amyloidosis have a clonal immunoglobulin abnormality, which could result in misdiagnosis and inappropriate administration of chemotherapy 55 . Nuclear scintigraphy using The presence of heart failure with preserved ejection fraction and/or proteinuria with progressive renal failure in a patient with a monoclonal protein should raise the suspicion of systemic monoclonal immunoglobulin light chain (AL) amyloidosis. The involvement of the peripheral and autonomic nervous systems as well as hepatomegaly associated with malabsorption and weight loss should also trigger the diagnostic process. In patients with a monoclonal protein and abnormal free light chain ratio, an unexplained increase in the amino-terminal fragment of type B natriuretic peptide (NT-proBNP) >332 ng per litre and/or the presence of albuminuria >0.5 g per day are diagnostic red flags. In the presence of cardiac involvement, technetium-labelled bone scintigraphy tracers, such as Tc-labelled pyrophosphate (PYP), help in distinguishing AL amyloidosis from transthyretin (ATTR) amyloidosis. In patients without serum and urinary monoclonal protein, a positive scan (grade 2 or greater) is indicative of ATTR amyloidosis. In patients with a monoclonal protein, biopsy sampling of abdominal fat and lip salivary glands provides 85% sensitivity for the diagnosis of AL amyloidosis. In patients with a negative biopsy sample who present with a high index of suspicion of heart involvement, according to symptoms, echocardiography and cardiac MRI should be used promptly. If positive, cardiac biopsy and possibly amyloid typing are recommended. a Amyloid should be typed with mass spectrometry or immunohistochemistry by an expert amyloid pathologist. MGUS, monoclonal gammopathy of undetermined significance. Tc-labelled 3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) can be useful in differentiating cardiac AL amyloidosis from the ATTR type 56, 57 . The mechanism by which these bone tracers bind to amyloid deposits is unclear, but substantial cardiac uptake occurs in virtually all patients with ATTR amyloidosis and in only ~40% of those with cardi ac AL type; among the latter, ~10% demonstrate substantial ATTR-like grade 2 or grade 3 uptake 58 .
When an amyloid deposit is detected as AL using mass spectroscopy, systemic amyloidosis should be distinguished from localized disease, as this determines management strategies. Localized deposits of AL that do not require systemic chemotherapy can be observed in the bladder, larynx, stomach, colon, skin, eyelids, lung and urinary tract. Only systemic amyloidosis requires systemic therapy, as localized disease usually has a very good prognosis 4 . A thorough evaluation for other areas of organ dysfunction can usually distinguish systemic from localized AL amyloidosis.
Screening and prevention
A substantial delay to diagnosis until after advanced organ damage has already ensued is still common for AL amyloidosis, and although therapeutic advances have been made, this results in high mortality rates owing to cardiac involvement and progression to end-stage renal disease in the first few months after diagnosis 8, 59 . The clinical manifestations of systemic AL amyloidosis resemble the symptoms of more common conditions found in elderly individuals, therefore, appropriate diagnostic testing is usually initiated only several months after the onset of symptoms. Indeed, AL amyloidosis was diagnosed >1 year after the onset of symptoms in 40% of patients in one study 60 . Delays in diagnosis of AL amyloidosis are also common in patients with diagnosed MGUS despite the appearance of amyloid-related symptoms 61 . Indeed, a monoclonal component with increased free light chain ratio can be consistently detected in the sera of patients with MGUS who eventually develop AL amyloidosis at least 4 years before the diagnosis 62 . Thus, patients with asymptomatic monoclonal gammopathy, MGUS or smouldering multiple myeloma with an abnormal free light chain ratio are at risk of developing AL amyloidosis and should be the target of screening programmes. The heart and/or the kidneys are involved in >95% of patients with systemic AL amyloidosis, and biomarkers with 100% sensitivity are available to detect the presence of cardiac and renal damage. For example, increased levels of NT-proBNP in serum can detect cardiac involvement in systemic AL amyloidosis before symptoms manifest with 100% diagnostic sensitivity 63, 64 . When glomerular filtration rate (GFR; a marker of kidney function) is preserved, albuminuria can detect renal involvement at earlier disease stages when progression to end-stage renal disease can be almost invariably prevented 59 . Accordingly, assessment of NT-proBNP levels and for albuminuria should be integrated into the regular follow-up panel of patients with MGUS and an abnormal free light chain ratio 65, 66 . More than 95% of patients with AL amyloidosis have elevated NT-proBNP or albuminuria, and this approach can lead to the detection of pre-symptomatic systemic AL amyloidosis, which can be effectively treated with very good outcomes 67 .
Patient risk stratification
The survival of patients with systemic AL amyloidosis is heterogeneous depending on the severity of cardiac dysfunction at the time of diagnosis. Patients with diagnosis late in the clinical course (when heart damage is often irreversible) have a median survival of 3-6 months 68 , whereas patients without cardiac involvement can survive for many years, even if they fail to respond to first-line therapy. Similarly, the early diagnosis and effective treatment of patients with renal involvement almost abolishes the risk of progression to end-stage kidney disease and dialysis, whereas late diagnosis during the advanced stages of disease is associated with a higher risk of progression despite treatment 59 . This heterogeneity requires accurate prognostic stratification to establish the best therapeutic approach, which needs to balance treatment intensity and speed of action with patient frailty. Moreover, patient stratification is necessary for comparing the results of clinical trials.
The current staging systems for systemic AL amyloidosis are based on the levels of circulating markers of cardiac and renal damage, and B cell clonal disease. One cardiac staging system is based on the levels of NT-proBNP and cardiac troponins and was devised by the Mayo Clinic and modified by European investigators to improve the discrimination of very-high-risk patients [68] [69] [70] [71] ( fig. 6a ). This cardiac staging system is the most widely used for clinical trial design and to determine patient management. This staging system was modified to include clonal burden, as assessed by bone marrow plasma cell infiltration and dFLC (difference between disease-associated and uninvolved circulating free light chain) concentration, which have independent abilities to predict survival. Patients with AL amyloidosis and a bone marrow plasma cell infiltrate of >10% have poorer survival that is comparable to patients with concomitant overt multiple myeloma 72 . Individuals with a very low (<50 mg per litre) dFLC level have a significantly better outcome irrespective of cardiac stage [73] [74] [75] . The Mayo Clinic group incorporated the dFLC level (with a cut-off value of 180 mg per litre) in their revised staging system 76, 77 ( fig. 6b) . A renal staging system predicting the progression to dialysis has also been proposed and validated by European investigators 59, 78 ( fig. 6c) . Although the severity of renal involvement does not directly affect survival, it impacts kidney survival and QOL and might reduce access to effective therapy. Other biomarkers have been shown to predict outcomes in systemic AL amyloidosis but have not been integrated into staging systems so far. For instance, high levels of von Willebrand factor were found to be associated with early death 79 . More recently, growth differentiation factor 15 emerged as a predictor of both survival and progression to dialysis 80 .
Management
The aims of therapy are rapid elimination of the amyloid precursor and improved reabsorption of amyloid deposits to rapidly ameliorate cardiac function to improve patients' QOL and survival. The suppression of amyloid light chain synthesis is effectively achieved using chemotherapy (both conventional and high dose) in combination with peripheral blood autologous haematopoietic stem cell transplantation and, more recently, with immunotherapy targeting the B cell clone. Immunotherapies promoting the reabsorption of amyloid deposits are in clinical development 7 . Ultimately, the types of therapy used depend on the patient's risk classification.
Changes in levels of dFLC, NT-proBNP, proteinuria or GFR are used to assess treatment efficacy; indeed, an international effort established and validated haematological and organ response criteria in AL amyloidosis (Table 3) . The aim of chemotherapy should be the rapid achievement of very low absolute values (rather than percent reductions) of dFLC, which are associated with improvements in organ dysfunction and prolonged survival 81, 82 . Emerging data indicate that minimal residual disease may be responsible for residual organ disease despite what is generally considered good-quality haematological response. If the available preliminary data are confirmed, the coexistence of persistent organ dysfunction in the absence of other causes and minimal residual disease could prompt further chemotherapy to obtain minimal residual disease negativity, improving the likelihood of organ response 83, 84 . Assessment of treatment response should be frequent and should be carried out after at least every 2 cycles of chemotherapy or 3 months after stem cell transplantation and more frequently for patients with severe cardiac involvement. Patients failing to achieve a good response should be rapidly shifted to alternate rescue regimens. Organ response usually closely follows haematological response and can be assessed as early as 3 months after treatment initiation, but may continue to improve afterwards.
Treatment of low-risk patients
The goal of treatment for AL amyloidosis is targeting the underlying clonal plasma cell dyscrasia, aiming for rapid and deep haematological responses. High-dose intravenous melphalan conditioning followed by autologous peripheral blood stem cell transplantation (HDM-SCT) has been used as treatment for highly selected patients with AL amyloidosis since the first reports in the mid-1990s 85 . The results of studies of HDM-SCT at single centres and multiple centres are reported in Supplementary Table 1. The risk of major complications, including death, during stem cell mobilization and collection is ~15% 86 , and early treatment-related mortality is 2-15% after transplantation 87 ; thus, appropriate patient selection is key to reducing in morbidity and mortality. Eligibility criteria for HDM-SCT vary between centres but broadly require a confirmed tissue diagnosis of amyloidosis, clear evidence of a clonal plasma or B cell dyscrasia and adequate measures of performance status (a grade of 0-2 at the Eastern Cooperative Oncology Group (ECOG) performance status), cardiac function (a left ventricular ejection fraction of >40%, cardiac biomarkers below the thresholds and New York Heart Association (NYHA) class <3), pulmonary function (O 2 saturation >95% on room air), hepatic function (total bilirubin level <2 mg per dl) and haemodynamic stability (baseline systolic blood pressure >90 mmHg). Patients on haemodialysis or peritoneal dialysis are not excluded at some centres if other eligibility criteria are met 88 . Several studies have evaluated the efficacy and morbidity associated with HDM-SCT. One multi centre randomized controlled trial demonstrated similar clonal haematological responses and superior overall survival with conventional chemotherapy using oral melphalan and dexamethasone compared with HDM-SCT. However, this trial had major limitations including a treatment-related mortality of 24% in the HDM-SCT treatment arm and a small sample size; additionally, 20% of patients were excluded in the HDM-SCT arm, and 13 patients were unable to proceed to transplant 89 . However, a landmark analysis of surviving patients at 6 months failed to show superiority of overall survival in this randomized trial. Another report from the Center for International Blood and Marrow Transplant Research registry showed improvement in overall survival and a reduction in early mortality with excellent 5-year survival after HDM-SCT 90 . A dose-adapted melphalan strategy, with dose reductions depending on renal and cardiac parameters and age, increases the potentially suitable patient population for HDM-SCT and can lead to prolonged survival, especially if a haematological complete response is achieved 91, 92 . Lower doses of melphalan could reduce treatment-related toxicity but also lower haematological responses 93 . The largest experience with HDM-SCT for AL amyloidosis is from the Mayo Clinic and Boston University. In all three staging systems, higher disease stages convey a higher risk of end-stage renal disease.
In 421 patients treated with HDM-SCT at Boston University, treatment-related mortality was 11% overall and decreased to 6% in the last 5 years of the study 94 . Median event-free survival was 2.6 years, whereas overall survival was 6.3 years, and 1 year after treatment, 43% of evaluable patients achieved a complete haematological response and 78% experienced an organ response. For patients who achieved complete response, the median event-free survival was 8.3 years and the median overall survival was 13.2 years. 195 patients did not obtain complete response, and of these patients, 52% had an organ response, the median event-free survival was 2.0 years, and median overall survival was 5.9 years. 26% of the patients who did not achieve complete response remained clinically stable at 5 years of follow-up. An expanded series of 647 patients from the same centre demonstrated haematological relapses in 38.5% of patients who achieved complete response at a median of 4.32 years 95 . In a series of 422 patients from the Mayo Clinic, treatmentrelated mortality was 12% in patients treated before 2006 and 7% after 2006. Troponin T levels >0.06 ng per litre and NT-proBNP levels >5,000 pg per ml were associated with high treatment-related mortality, whereas patients with both markers below the thresholds had a treatment-related mortality of 1% 96 . The first report of any organ improvement with respect to renal response following HDM-SCT demonstrated 97 a renal response in 36% of patients 12 months after treatment 97 . This response was defined as a 50% reduction in 24-hour urinary protein excretion in the absence of a ≥25% reduction in creatinine clearance. Renal response rate was 71% in patients with a complete haematological response and 11% for those with persistence of the plasma cell dyscrasia. Since this initial report, improvements in QOL 98 , hepatic responses 99 and cardiac responses 100, 101 after HDM-SCT have been reported. Similar to renal response, clinical responses in other organ systems are more evident in patients with haematological responses and can take up to 6-12 months or longer to occur. Given the association between survival and organ responses with haematological response after stem cell transplantation, strategies to improve haematological complete response rates after this procedure have been an important focus. These include induction therapy before HDM-SCT 102, 103 , novel conditioning regimens 104 and consolidation therapy 105 .
The role of induction therapy for bone marrow plasmacytosis of >10% remains controversial; however, it is recommended by some clinicians 72, 106 . Haematological relapses or progression after HDM-SCT occurs in 36-38% of patients at a median of 2.0-4.3 years after treatment 95 . Late relapses >20 years after HDM-SCT have also been reported 95 . Others have reported an event-free survival of ~4 years in patients undergoing stem cell transplantation for AL amyloidosis, independent of haematological response, and superior event-free survival in individuals achieving complete response at 1 year after transplant 107 . Table 2 ); this treatment was the standard for more than a decade for patients not undergoing HDM-SCT. MDex is very well tolerated in intermediaterisk patients, and a haematological response is reached in up to 76% of patients, with very good partial response or complete response in 60% of cases when full-dose dexamethasone can be given 77 . Regimens using bortezomib (a proteasome inhibitor) are now considered the upfront standard of care in most patients with AL amyloidosis. In the largest retrospective study of first-line treatment with cyclophosphamide, bortezomib and dexamethasone (CyBorD), the overall haematological response rate was 66% in patients with stage II or stage IIIa disease, with a very good partial response or complete response in 47% of patients 108 . In studies comparing bortezomibbased combinations with previous standards of careMDex and a combination of cyclophosphamide, thalidomide and dexamethasone -response rates were higher with bortezomib treatment when combined with alkylating agents and dexamethasone, although this did not translate into a survival advantage 110, 111 . In an international phase III study, bortezomib plus MDex demonstrated a higher haematological response rate than MDex alone (81% versus 57%, P = 0.005) 112 . On the basis of these data, intermediate-risk patients who are not eligible for HDM-SCT should be treated with bortezomib-based regimens, provided they do not have contraindications, such as peripheral neuropathy or fibrotic lung disease. B cell clonal characteristics and patient characteristics should be considered when choosing the most appropriate drug combinations. For example, treatment with bortezomib plus MDex can overcome the effects of a gain of 1q21 (which confers a poorer outcome with oral melphalan) and t(11;14) (which confers a poorer outcome with bortezomib) [113] [114] [115] [116] . Cyclophosphamide and higher doses of dexamethasone do not significantly improve response rates and survival of patients with AL amyloidosis receiving bortezomib 117 . Treatment with bortezomib plus dexamethasone alone or in combination with cyclophosphamide is preferred in patients with potentially reversible contraindications to autologous stem cell transplantation, as these treatments will not destroy the patient's stem cells, and in patients with renal failure for whom melphalan dose adjustments are usually required. Intermediate-risk patients in whom bortezomib is contraindicated owing to pre-existing peripheral neuropathy can be treated with MDex or immunomodulatory drug-based combinations, whereas patients without substantial peripheral neuropathy can receive a combination of cyclophosphamide, thalidomide and dexamethasone. The haematological response rate to this combination is 68-79%, and at least a very good partial response can be observed in 45% of patients 111, 118 . However, substantial toxicity has been reported with thalidomide in patients with AL amyloidosis 119, 120 . Combining lenalidomide and MDex for frontline therapy led to haematological response rates between 38-68% and substantial myelosuppression [121] [122] [123] . Lenalidomide, cyclophosphamide and dexamethasone combinatorial therapy has also been used as frontline therapy and has haematological response rates ranging from 46-60%, with at least a very good partial response in 40-43% of patients [124] [125] [126] . High-risk patients represent ~20% of all individuals with AL amyloidosis and represent a challenge owing to advanced cardiac stage (IIIb) dysfunction or severe heart failure (NYHA class III or class IV). So far, no treatment regimen can substantially alter the course of the disease in these patients, with median survival not exceeding 7 months 127 . Nevertheless, the few patients (~20%) who survive long enough (1-3 months) to take advantage of the response to chemotherapy can enjoy prolonged survival 128 . High-risk patients can be treated with lowdose combinations of the drugs used in intermediaterisk subjects, with weekly dose escalation on the basis of tolerability with close monitoring 129 . Although high-risk patients are typically excluded from clinical trials, there is interest in whether therapies directed at the amyloid itself may offer better hope.
Treatment of intermediate-risk and high-risk patients

Treatment of relapse
Patients with relapsed disease have a good prognosis, with remarkably longer survival than patients with refractory disease 130, 131 . A few studies report the rate of relapse after initial treatment. The Boston University group reported a 38.5% rate of relapse after complete response following stem cell transplant 95 . A study by the Mayo Clinic investigators revealed haematological relapse or progression in 36% of patients who underwent HDM-SCT 130 . The Pavia group reported that 35% of patients who received non-transplant upfront therapy needed second-line therapy after a median follow-up of 41 months 131 . No consensus has been reached on the criteria to commence rescue therapy in patients with relapsing disease 132 . Cardiac progression as assessed by increase in NT-proBNP should not be awaited because it is associated with shorter survival 131 . Patients with relapsed disease can be treated by repeating the upfront therapy, if possible, although this is associated with a decreased time to re-treatment without a reduction in overall survival compared with those seen in patients who are treated with a different regimen at relapse 133 . For patients who have relapsed after autologous stem cell transplantation, treatment using a proteasome inhibitor is indicated. If the patient maintains eligibility and stem cells are available, a second autologous stem cell transplant may also be considered 130 . Although immuno modulatory drugs are less often considered as the first choice for patients with newly diagnosed disease, they are often the backbone of treatment of refractory patients ( fig. 7; Supplementary  Table 3 ). Lenalidomide can overcome resistance to alkylating agents, proteasome inhibitors and thalidomide, inducing a haematological response in patients refractory to these agents 124, 125, [134] [135] [136] [137] . However, lenalidomide can worsen renal failure in patients with substantial proteinuria 138 . Pomalidomide is one of the most powerful agents in refractory AL amyloidosis, being able to rescue patients refractory to alkylators, firstgeneration and second-generation proteasome inhibitors and lenalidomide [139] [140] [141] . Haematological response to pomalidomide is obtained rapidly, in a median time of 1-2 months, and is observed in 48-68% of patients (with a very good partial response or complete response in 18-30%) [139] [140] [141] and carries a manageable toxicity profile. Newer agents have also been evaluated in patients with relapsed or refractory disease. In a phase II trial, the oral proteasome inhibitor ixazomib induced haematological response in 56% of 21 previously treated patients, with all the 5 patients who had not been previously exposed to bortezomib achieving at least a very good partial response, and is currently being tested in a randomized phase III trial in patients with relapsed and/or refractory disease (NCT01659658) 142 . The humanized anti-CD38 monoclonal antibody daratumumab is one of the most promising new agents 143, 144 and is being moved to frontline therapy in clinical trials. A recently published series of previously treated individuals who received daratumumab reported a rapid (median 1 month) haematological response in 76% of patients, with 36% of patients having complete responses 145 . Nature reviews | Disease Primers | article citation iD: (2018) 4:38 13 P r i m e r 0123456789();
Amyloid-directed immunotherapy
Although chemotherapy reduces the plasma cell burden and ultimately the production of the amyloidogenic light chain protein, this therapy does not degrade amyloid deposited in tissues, although amyloid does slowly resorb from the body once the amyloid precursor has been suppressed. To this end, three monoclonal antibodies have been developed to target existing amyloid deposits: NEOD001, 11-1F4 and an anti-SAP antibody. In a phase I/II study, patients with AL amyloidosis who had completed at least one previous anti-plasma cell-directed therapy and had a partial haematological response or better, and with persistent organ dysfunction received NEOD001, which targets amyloid fibrils 146 . No drug-related serious adverse events or discontinuations were observed among the 27 treated patients, and of the 14 patients who could undergo cardiac evaluation, 8 responded and 6 were stable, whereas of the 15 patients who could undergo renal evaluation, 9 responded and 6 were stable. However, despite these results, a phase III trial and a phase IIb placebo-controlled trial failed to confirm the positive effects of NEOD001 on cardiac involvement, and the development of this antibody was discontinued. This emphasizes the need for controlled studies based on robust end points to introduce novel therapies for AL amyloidosis.
The murine monoclonal antibody 11-1F4 recognizes an amyloid-associated conformational epitope in human light chain-related fibrils 147 . In studies of mice with human amyloidomas (soft tissue tumours of AL composition created in the hindquarters of mice), 11-1F4 induced a rapid reduction of the masses without toxicity 148 . In an open-label, dose-escalation, phase I trial, 11-1F4 was well toler ated by all treated patients 11;14) ), which confers a poor response to bortezomib (but these patients are sensitive to standard-dose melphalan), and can be used in patients with gain of 1q21, who are poorly responsive to standard-dose melphalan but who are sensitive to bortezomib. However, melphalan can impair stem cell collection in patients who are potential candidates for HDM-SCT; CyBorD should be preferred in these patients. Patients presenting with peripheral neuropathy or fibrotic lung disease should avoid bortezomib owing to its potential neurotoxicity and lung toxicity. Patients with severe cardiac involvement (20-25% of patients with AL amyloidosis) with very high serum concentrations of the amino-terminal fragment of type B natriuretic peptide (NT-proBNP) ( >8,500 ng per litre) and New York Heart Association (NYHA) class of III or greater are considered high risk and represent an unmet need. Bortezomib-based regimens, either attenuated or full-dose under close observation in a critical care unit, can benefit 30-40% of these patients, although the overall survival is poor (4-7 months). In these patients, cardiac transplantation should be considered, followed by HDM-SCT. The treatment of relapsing and/or refractory patients is mostly based on immunomodulatory drugs (IMiDs), with pomalidomide emerging as well-tolerated and fast-acting. Daratumumab is highly effective and, on the basis of the outcome of an ongoing phase III trial, might be moved to upfront therapy in combination with bortezomib-containing regimes. ECOG, Eastern Cooperative Oncology Group; MDex, melphalan and dexamethasone. A third antibody approach that is potentially applicable to all types of amyloidosis targets SAP. Depletion of circulating SAP using miridesap enables the subsequent administration of the humanized anti-SAP antibody, dezamizumab, which binds to residual SAP in amyloid deposits and induces a macrophage response that triggers their rapid removal 150 . In an open-label, dose-escalation, phase I clinical trial (NCT01777243), 16 patients with amyloid A amyloidosis (formerly known as secondary amyloidosis), AL amyloidosis and apolipoprotein AI-derived (AApoAI) amyloidosis received a single dose of antibody. Mild infusion reactions and rashes were observed in some patients who received larger doses, but no serious adverse events were reported. SAP scintigraphy confirmed amyloid removal from the liver, spleen and kidneys, which was associated with improvements in liver function 151 . Further attempts to evaluate the safety, pharmacokinetics and dose-response effects of up to three cycles of miridesap including updating the accrual to dezamizumab to 23 patients (NCT01777243) demonstrated good tolerability and progressive dose-related clearance of amyloid 150 . A phase II trial of monthly repeated treatments in patients with cardiac AL and ATTR amyloidosis is ongoing (NCT03044353).
Supportive therapy
Therapy for patients with AL amyloidosis is not limited to treating the underlying clone; it also includes supportive therapy. These patients with AL amyloidosis typically have a large symptom burden ( fig. 3) owing to their underlying amyloid-induced organ dysfunction, producing poor functional status at baseline and making them more susceptible to chemotherapy-induced toxicity.
Cardiac disease. Patients with cardiac dysfunction owing to AL amyloidosis should be managed differently from those with cardiac dysfunction caused by other factors. Patients with AL cardiomyopathy do not typically tolerate β-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. The sinus tachycardia for many of these patients is physiological and necessary to maintain adequate cardiac output. Careful diuresis, avoiding over-diuresis, and avoidance of drugs that may reduce cardiac output are the best strategies for the treatment of cardiac dysfunction owing to AL amyloidosis. Loop diuretics are most commonly used, of which torsemide has a better bioavailability than furosemide. Spironolactone and metolazone can be used as adjunctive diuretics. Superimposed nephrotic syndrome and autonomic dysfunction make the management of amyloid cardiomyopathy even more challenging because both hamper diuresis. In patients with atrial fibrillation or flutter, amiodarone is the best-tolerated drug. Atrial ablation and atrioventricular nodal ablation can also be of value 152 . Careful use of digoxin in patients with atrial fibrillation or flutter and low blood pressure should not be discounted 153 . Ventricular arrhythmias, especially premature ventricular contractions, are common, and the presence of couplets and complex arrhythmias are prognostic 154 ; however, defibrillators are less effective in patients with AL amyloidosis in part because pulseless electrical activity is one of the more common preterminal events [155] [156] [157] [158] . Patients on β-blockers might have increased risk of bradycardia owing to complete atrioventricular block, and in one series, the pre-cardiac arrest rhythm was bradycardia in all eight patients, including a complete heart block in six patients 159 . Which patients with AL amyloidosis might benefit from cardiac defibrillations is unclear. Pacemakers can be useful with patients with chronotropic incompetence.
Doxycycline has demonstrated anti-amyloid activities in vitro and in vivo. Doxycycline interferes with amyloid formation in a mouse model of AL amyloi dosis 160 and abrogates light chain toxicity in vitro 161 . Indeed, the addition of doxycycline to standard chemotherapy reduced early mortality in cardiac AL amyloidosis in a retrospective case-matched study 162 . An international phase III trial is ongoing in newly diagnosed patients with advanced cardiac involvement comparing standard of care (that is, bortezomib-based therapies) versus standard of care plus doxycycline (NCT03474458).
Orthotopic heart transplantation might be used in selected patients 163, 164 . Key determinants for the best outcomes following transplantation include limiting candidates to those who have lower tumour burden, accepting candidates who have clinical organ involvement limited to the heart and administering chemotherapy that is effective against the clone. However, most patients do not satisfy these criteria. Many patients awaiting transplant do not survive long enough to receive an orthotopic heart. For patients who do receive transplantation, 5-year overall survival ranges from 18% to 66% 165 . Some of the best results have been in patients who have HDM-SCT after their cardiac transplant 166, 167 , but with improving therapies directed at the plasma cell clone, one could consider other non-stem-cell-transplantation options.
Renal disease. For AL amyloidosis nephrotic syndrome, nephrologists might recommend angiotensinconverting enzyme inhibitors on the basis of data from patients with diabetic nephropathy. Whether these drugs provide benefit in some patients with AL amyloidosis is unknown, but it is clear that they might be harmful in patients with coexistent AL cardiomyopathy or autonomic dysfunction. For patients with very low serum albumin levels, diuretics alone might be insufficient to diurese them; albumin diuresis can be helpful to return patients closer to their dry weight. Peritoneal dialysis and haemodialysis are options for patients who develop renal failure, but for patients with either coexisting cardiac or autonomic involvement, haemodialysis can be P r i m e r 0123456789(); a challenge owing to hypotension 168 . Renal transplantation is an option for some patients with AL amyloidosis. However, amyloidosis can occur in a transplanted kidney 169, 170 but should be less of an issue with highly effective anti-plasma cell-directed therapies. In one study, among 22 patients receiving a kidney transplant in the United Kingdom, no renal graft failures were reported at 4.8 years, 1-year overall survival was 95%, and 5-year overall survival was 67% 169 . In a Mayo Clinic series, overall survival was 84% at 1 year and 76% at 5 years in 19 patients with AL amyloidosis who received kidney transplantation, and no graft failures were reported 170 .
Other symptoms. Autonomic neuropathy alone or with other organ involvement is very difficult to manage. In patients with autonomic neuropathy without cardiomyopathy and nephrotic syndrome, a high-salt diet and fludrocortisone administration are useful adjuncts to manage hypotension, as are 40 mmHg compression stockings -either thigh high or waist high. Even among patients with cardio myopathy, midodrine, pyridostigmine or droxidopa (not fludrocortisone) might be required to maintain adequate blood pressure. Diarrhoea owing to either autonomic neuropathy or gastrointestinal amyloid deposits can be managed using anti-motility agents, bile acid binders, octreotide and even central parenteral nutrition.
Clinical improvement in peripheral neuropathy is rare with traditional chemotherapy, and it is infrequent even with high-dose chemotherapy. Several drugs might be useful for painful neuropathy, such as gabapentin, pregabalin and duloxetine, and topical therapies containing lidocaine, amitriptyline and ketamine might also be beneficial. Collaborative symptom management with rehabilitation physicians and/or palliative medicine teams might also be of value.
Quality of life QOL is deeply, strongly and broadly affected in patients with systemic AL amyloidosis owing to multiorgan involvement and treatment. However, a consistent and standardized measurement of QOL in AL amyloidosis is not available. QOL measures can predict several outcomes such as job loss, work productivity, health expenditures and even mortality, and many different tools are available to assess QOL. Commonly used tools to evaluate QOL in the area of stem cell transplantation are the European Organization for Research and Treatment of Cancer (EORTC) QOL-30 and Functional Assessment of Cancer Therapy Bone Marrow Transplant (FACT-BMT) scale instruments. The medical outcomes study 36-item short form general health survey (that is, the SF-36) questionnaire is the most reliable, rigorously validated and widely used patient-reported outcome measure. The SF-36 health survey is currently the most used generic patient-reported outcome measure in studies of patients with AL amyloidosis, and early qualitative validation studies support its use in this population. Consistent evidence of the psychometric properties of the SF-36 in both community-based and clinic-based samples of patients with AL amyloidosis has been reported 171 . Aside from the SF-36, other outcomes scales, such as the Haematology Patient Reported Symptom Screen, can predict survival and assess QOL in patients with AL amyloidosis. This tool is composed of three questions about fatigue, pain and QOL 172 . In one observational study 173 , significant improvements in vitality, social functioning, role-emotional and mental health were demonstrated after HDM-SCT in patients with AL amyloidosis 173 . Lower pretreatment SF-36 physical component scores were associated with a greater risk of mortality in patients receiving HDM-SCT or in those who received non-stem cell transplant chemotherapy regimens and during follow-up periods 173 . An improvement in SF-36 scores after HDM-SCT was also demonstrated in another observational study 98 ; mental component summary scores reached the population norm 1 year after stem cell transplantation, and physical component summary scores reached the population norm 2 years after stem cell transplantation. In addition, certain domains of SF-36 scores could be used to predict survival following HDM-SCT; a higher physical function score was associated with early post-stem cell transplantation survival, and higher vitality scores were associated with late post-stem cell transplantation survival beyond 1 year 98 . The use of QOL assessments at every physician visit or treatment might provide valuable insights for treating rare conditions like AL amyloidosis. The effect of systemic AL amyloidosis on the QOL of patients' care givers has not been studied. Similarly, the financial implications of this multiorgan disease on patients and caregivers -although tremendous -are not well documented.
Outlook
Great advances have been made during the past decade in understanding the mechanisms of AL amyloid osis and in treatment, which have translated into better QOL and improved survival. However, less than one-quarter of patients achieve a complete and long-lasting haematological remission and survive for >10 years 7, 46 . Production of AL amyloid light chain precursors by clonal plasma cells still cannot be adequately suppressed in most cases, and the function of vital organs impaired by amyloid improves in only one-quarter of patients on an intention to treat basis 7 . Furthermore, ~20% of patients are diagnosed at a late stage, when cardiac damage is very advanced, and survival can be measured in weeks. At the present time, therapy directed towards the underlying clonal disease improves the outcome in ~30% of these patients, but anti-amyloid therapies might increase survival in additional patients. Improved awareness of AL amyloidosis and diagnostic methods to enable earlier diagnosis before cardiac damage has become irreversible are some of the major aims of current research.
In addition, the search for new drugs is ongoing. For instance, the proteotoxicity exerted by amyloid, misfolded, light chains could be harnessed for therapy. The distinctive perinuclear distribution of mitochondria in plasma cells from patients with amyloidosis as compared with plasma cells from patients with multiple myeloma and individuals with MGUS is indicative of oxidative stress, which was further supported by the abundance of transcripts encoding organelle-resident redox sensors 174 . Moreover, the expression of amyloidogenic light chains in myeloma cells altered cell growth and proteostasis through proteotoxicity and conferred sensitivity to bortezomib; accordingly, proteasome inhibitors are a targeted therapy in AL amyloidosis and might direct future anti-clone drug development 174 . Drugs targeting the ubiquitin-proteasome system are under development for multiple myeloma to overcome resistance to proteasome inhibitors 175 , and preliminary data obtained in primary amyloidogenic plasma cells indicate potential activity for AL amyloidosis. Researchers are focusing their efforts on investigation of the biological characteristics of amyloidogenic B cell clones and on development of novel agents and their optimal use in combinations to provide high rates of eradication 7, 176 . Sensitive technologies based on mass spectrometry are being developed to detect trace amounts of the amyloid light chain, along with next generation flow cytometry and sequencing for the detection of minimal residual disease [177] [178] [179] [180] . Complete eradication of the clonal disease is expected to be associated with higher recovery of organ dysfunction and long-lasting remission and might become the next therapeutic goal. Other open questions include the heterogeneity of organ involvement in a single patient and the mechanisms underlying the vital organ dysfunction caused by amyloidosis, particularly in the heart. Pathogenetic mechanisms being studied include direct disruption by amyloid of the myocardial architecture, coronary vasculature and autonomic nerves and cytotoxicity of amyloid fibrils and their soluble precursors 2, 33, 181 . Although some ancestral models of amyloidosis (such as in Caenorhabditis elegans and zebrafish) 161, 182 have been used to investigate the mechanism of amyloid cardiac damage, other animal models of AL amyloidosis are urgently needed. The development of novel sensitive biomarkers and imaging technologies, notably including tissue characterization with MRI, for the detection and quantification of organ involvement and damage is already facilitating earlier diagnosis and improved evaluation of the efficacy of new and existing therapies 45, 183, 184 . The outcomes of ongoing trials investigating passive immunotherapy aimed at accelerating removal of amyloid will shortly shed exciting new light on this field 149, 150 and inform further research aimed at improving recovery of the function of hearts damaged by amyloid, which is a prerequisite to substantially improving the overall outlook of this increasingly treatable disease.
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